Clay Siegall is a scientist and entrepreneur. He studied at the University Of Maryland in College Park, Maryland where he received a bachelor’s of science in zoology. Clay Siegall later went on to study genetics at George Washington University in Washington D.C., where he graduated with a PhD.
Mr. Clay Siegall has a long history of working in the pharmaceutical and healthcare industry. In 1988, he joined the National Cancer Institute of the National Institutes of Health. He served at the National Cancer Institute for almost three years, offering insight into cancer treatment and diagnosis. Siegall later joined the Bristol-Myers Squibb Pharmaceutical Research Institute, where he worked on developing new drugs and medicine for Bristol-Myers Squibb. He would work at the Bristol-Myers Squibb Pharmaceutical Research Institute until 1977, a period of six years.
In 1998, Clay Siegall took a major risk and started a biotechnology company called Seattle Genetics. He currently holds the position of chief executive officer, company president and chairman of the board of directors. Seattle Genetics is a biotechnology research and development company that focuses on creating alternative treatments for cancer.
A Closer Look At Seattle Genetics
Seattle Genetics is one of the first companies to develop antibody-drug conjugate treatments for cancer. This is a new kind of cancer treatment that uses the targeted abilities of antibodies to specifically target cancer causing cells with new drugs to kill the cancerous cells. By specially targeting cancerous cells, healthy cells can be avoided leading to a more effective, less harsh and more successful cancer treatment.
The first FDA approved antibody-drug conjugate drug released by Seattle Genetics was called ADCETRIS® and it gained FDA approval in 2011. This new cancer treatment medicine is now approved in over 60 different countries thanks to a joint partnership with Takeda Pharmaceutical Company of Japan. Seattle Genetics continues to develop and research new ADC treatment options and has dozens of new drugs in its pipeline.
Seattle Genetics is now a publicly trade company that has had over a billion dollars in public and private investment. It is based in the Seattle, Washington metro area and is a rapidly expanding company. CEO, Clay Siegall, has recently announced the hiring of hundreds of new employees in the future and new research and warehouse space.